Lipoatrophic Diabetes Mellitus

A type of diabetes mellitus that is characterized by severe INSULIN RESISTANCE and LIPODYSTROPHY. The latter may be generalized, partial, acquired, or congenital (LIPODYSTROPHY, CONGENITAL GENERALIZED).

Also Known As:

Networked: 69 relevant articles (8 outcomes, 5 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Insulin Resistance
2.	Congenital Generalized Lipodystrophy (Berardinelli-Seip Congenital Lipodystrophy)
3.	Hepatomegaly
4.	Diabetes Mellitus
5.	Type 2 Diabetes Mellitus (MODY)

Experts

1.	Nakao, K: 3 articles (04/2009 - 02/2000)
2.	Ebihara, Ken: 3 articles (12/2006 - 08/2004)
3.	Nakao, Kazuwa: 3 articles (12/2006 - 08/2004)
4.	Auclair, Martine: 2 articles (01/2022 - 01/2021)
5.	Fève, Bruno: 2 articles (01/2022 - 01/2021)
6.	Vigouroux, Corinne: 2 articles (01/2022 - 01/2021)
7.	Zammouri, Jamila: 2 articles (01/2022 - 01/2021)
8.	Ebihara, K: 2 articles (04/2009 - 06/2001)
9.	Hosoda, K: 2 articles (04/2009 - 06/2001)
10.	Masuzaki, H: 2 articles (04/2009 - 06/2001)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Lipoatrophic Diabetes Mellitus:

1.	LeptinIBA 08/13/2009 - "Leptin treatment ameliorates lipoatrophic diabetes in animal models and humans. " 01/01/2003 - "In particular we review the effects of recombinant human leptin in lean, obese, diabetic subjects and in patients with congenital leptin deficiency or lipoatrophic diabetes. " 06/01/2001 - "To explore the pathophysiological and therapeutic roles of leptin in lipoatrophic diabetes, we crossed LepTg/+ and A-ZIPTg/+ mice, producing doubly transgenic mice (LepTg/+:A-ZIPTg/+) virtually lacking adipose tissue but having greatly elevated leptin levels. " 09/01/1999 - "The phenotypes are in striking contrast to those of recently reported animal models of lipoatrophic diabetes and patients with lipoatrophic diabetes with reduced amount of leptin. " 12/28/2006 - "[Efficacy of leptin-replacement therapy in patients with lipoatrophic diabetes]."
2.	Glucose (Dextrose)FDA LinkGeneric 05/01/1990 - "Thus, the in vivo insulin resistance of lipoatrophic diabetes concerns not only glucose disposal but also hepatic glucose output and insulin secretion; in addition, the alterations of glucose metabolism were not the same in all subjects. " 11/01/2013 - "Lipid metabolites decrease glucose consumption and induce lipoatrophic diabetes. " 12/01/1984 - "Altered glucose transport conferring post-receptor insulin resistance to a patient with lipoatrophic diabetes." 04/15/2001 - "Lipoatrophic diabetes is an insulin resistance syndrome characterized by the complete or partial lack of adipose tissue and disturbances in lipid and glucose metabolism. " 03/01/1997 - "Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis?"
3.	Peptides (Polypeptides)IBA 07/01/1969 - "Lipoatrophic diabetes: an improved procedure for the isolation and purification of a diabetogenic polypeptide from urine." 06/01/1968 - "A diabetogenic polypeptide from hog and sheep adenohypophysis similar to that found in lipoatrophic diabetes." 04/01/1966 - "A diabetogenic polypeptide from bovine adenohypophysis similar to that excreted in lipoatrophic diabetes." 07/01/1980 - "Pancreatic B-cell function and abnormal urinary peptides in a boy with lipoatrophic diabetes and stenosis of the aqueduct of Sylvius."
4.	LipidsIBA 11/01/2013 - "Lipid metabolites decrease glucose consumption and induce lipoatrophic diabetes. " 01/01/2002 - "Lipoatrophic diabetes-associated utero-ovarian dysfunction: influence of cellular lipid deposition on norepinephrine indices." 04/15/2001 - "Lipoatrophic diabetes is an insulin resistance syndrome characterized by the complete or partial lack of adipose tissue and disturbances in lipid and glucose metabolism. " 03/01/1997 - "Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis?"
5.	Triglycerides (Triacylglycerol)IBA 09/01/1988 - "Thus a reduced peripheral clearance of triglyceride-rich lipoprotein could be an important determinant of lipoprotein abnormalities in lipoatrophic diabetes." 07/05/2002 - "These data support the hypothesis that reducing intracellular triglycerides in non-adipose tissues improves insulin sensitivity and suggest that further investigation of the role of PPARalpha agonists in the treatment of lipoatrophic diabetes is warranted." 04/01/1978 - "Effects of insulin and oral antidiabetic agents on the plasma triglyceride levels in lipoatrophic diabetes."
6.	Lipoproteins (Lipoprotein)IBA 09/01/1988 - "Thus a reduced peripheral clearance of triglyceride-rich lipoprotein could be an important determinant of lipoprotein abnormalities in lipoatrophic diabetes."
7.	FenfluramineIBA 06/01/1977 - "The rabbits got relapse of their lipoatrophic diabetes when the fenfluramine treatment was stopped. " 06/01/1977 - "Congenital generalized lipodystrophy and experimental lipoatrophic diabetes in rabbits treated successfully with fenfluramine."
8.	BezafibrateIBA 03/01/1997 - "Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis?"
9.	Troglitazone (Rezulin)FDA Link 08/15/2000 - "Therefore, troglitazone may have therapeutic benefit in lipoatrophic diabetes. " 08/15/2000 - "Troglitazone therapy improved metabolic control and increased body fat in patients with lipoatrophic diabetes. "
10.	Insulin (Novolin)FDA Link 09/01/2004 - "Lipoatrophic diabetes is characterized by the near absence of adipose tissue and the presence of insulin-resistant diabetes. " 06/01/2001 - "The A-ZIP/F-1 mouse (A-ZIPTg/+) is a model of severe lipoatrophic diabetes and is insulin resistant, hypoleptinemic, hyperphagic, and shows severe hepatic steatosis. " 12/01/1998 - "Lipoatrophic diabetes mellitus treated by continuous subcutaneous insulin infusion." 07/18/1984 - "The isolation and characterization of an insulin-releasing tetrapeptide from urines of patients with lipoatrophic diabetes." 06/29/1977 - "Binding of insulin to fibroblasts in lipoatrophic diabetes."

Therapies and Procedures

1.	Therapeutics 12/28/2006 - "[Efficacy of leptin-replacement therapy in patients with lipoatrophic diabetes]." 08/15/2000 - "Troglitazone therapy improved metabolic control and increased body fat in patients with lipoatrophic diabetes. " 08/05/2004 - "Long-term leptin-replacement therapy for lipoatrophic diabetes." 03/22/1991 - "[Successful insulin therapy in lipoatrophic diabetes]." 01/01/2006 - "Although leptin therapy has limited success in common obesity, it has impressive effects in congenital leptin deficiency, lipoatrophic diabetes and syndromes of severe insulin resistance. "
2.	Fat-Restricted Diet (Diet, Fat Restricted) 06/01/2003 - "However, when 1 g CLA/100 g diet was given to mice in a low fat diet (4 g fat/100 g diet), they showed a marked decrease in fat mass, but demonstrated symptoms of lipoatrophic diabetes, i.e., marked hepatomegaly and insulin resistance. "
3.	Liver Transplantation 04/15/2001 - "This article describes the first reported case of lipoatrophic diabetes with NASH leading to liver failure and liver transplantation. " 04/15/2001 - "Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation." 04/15/2001 - "NASH associated with lipoatrophic diabetes can recur after liver transplantation, and in this case, was accompanied by increased insulin requirements. "
4.	Kidney Transplantation 09/01/1978 - "Renal transplantation in a patient with lipoatrophic diabetes. "
5.	Glycemic Control 01/01/2000 - "With careful attention to glycemic control with use of U-500 insulin and strict avoidance of dietary fat, a 23-year-old woman with lipoatrophic diabetes maintained a pregnancy to 28 weeks. "